Pyxis Oncology (PYXS) Stock Forecast & Price Target

Pyxis Oncology is positioned favorably because MICVO has shown differentiated clinical activity in heavily pretreated 2L+ R/M HNSCC, with a 36% cORR, 94% DCR, mPFS of 6.2 months, and mOS not yet reached, while tolerability improved after dose capping as treatment-related discontinuations fell to 14.3% and Grade 3+ peripheral neuropathy eased. The outlook is further supported by a rich catalyst path, including updated OS data in 1H27, FDA feedback on dose selection in 1Q27, a corporate update in December, and planned initiation of the global Phase 3 HEADLINER trial in mid-27, which could validate MICVO’s value in a large 2L+ setting. Financially, the company ended the quarter with $57.0M in cash and, after a public offering on October 1, expects funding into 1H28, giving it runway to advance development while the market values the stock at a discount to its improving clinical profile.

Pyxis Oncology is vulnerable to unacceptable toxicity, weak efficacy signals, or adverse regulatory actions across its clinical-stage programs, any of which could materially undermine confidence in its lead asset and broader pipeline. The company’s dependence on micvotabart pelidotin and its early-stage development profile leaves limited room for setbacks, especially if clinical data fail to show a clear therapeutic advantage in solid tumors and head and neck squamous cell carcinoma. In that downside scenario, shares could trade near cash 12 months from now, with cash estimated at approximately $0.50, underscoring the risk of severe downside if development momentum deteriorates.